The cost of bringing a new drug to the market has recently been estimated by Forbes Magazine at $5 billion. This figure derives in large part from high attrition rates in the drug development pipeline ...
The generation of these cellular models for the study of diseases based on reprogrammed human cells is well established in pre-clinical studies - 2D cultures or organs-on-chip systems (OoCs) - and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback